Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
Vandana Singh
Fri, March 3, 2023 at 8:05 AM PST
https://finance.yahoo.com/news/despite-trial-failure-praxis-still-160535252.html
I guess if you're looking at today ....
Volatility is a trader's friend.
Wait - I thought RSHN was supposed to rocket to a dime IM-EE-DEE-ETLY! Market forces apply here too? Who knew?
RSHN - looks to be a sweet little pump - curious how this might go.
Some at .0199 .... looks OK for a swing.
I took a few nibbles in the .17's
yes, very sweet dip and recovery. volatile
QNTA especially with this float! what do they say - paytience.
some big blocks today.
nice bid @.058 got filled
QNTA
https://finance.yahoo.com/news/medolife-rx-completes-batch-production-130000438.html
Medolife Rx Completes Batch Production of Escozine® for FDA Submission
Quanta, Inc.
Thu, March 25, 2021, 6:00 AM
BURBANK, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has completed production of a batch of its lead drug candidate Escozine® and finalized analysis of the batch, which is now ready for submission to the US Food and Drug Administration (FDA) as a part of its Pre-Investigational New Drug (PIND #150335) filing as a potential treatment for the SARS-CoV-2 (COVID-19) virus.
As a part of its previously announced filing with the FDA on Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife, the Company was asked to produce a batch of the drug for further investigation by the agency. As such, Medolife produced the batch and performed analysis on it, confirming its microbiology and inclusion of its main ingredient. After successful completion of the analysis, the Company is now prepared to submit the batch according to the FDA’s request, moving the Company closer to FDA registration of the drug through the IND regulatory process. The Company hopes to complete the submission in the coming week.
Buy Low and sell high is how it's often done.
does look that way.
QNTA ... science looks legit
agreed.
QNTA is looking pretty good to me on all fronts - except the awareness front - but the fundies are good enough to let it ferment for a while
Medolife Rx Announces Pre-Clinical Results on Drug Candidate Escozine Showing Efficacy in Eliminating Cell Lines in Ovarian and Bladder Cancer
Quanta, Inc.
Tue, March 23, 2021, 6:00 AM
BURBANK, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today clinical trial results conducted on its lead drug candidate Escozine® where the drug eradicated in vitro bladder (SCaBER) and ovarian (OVCAR-3 and IGR-OV1) cancer cell lines when administered for 24 hours.
The study was conducted at one of the most prestigious academic research facilities in the United States. The goal of the study was to assess the viability of human bladder and ovarian cancer cells treated with Escozine®, the Company’s polarized drug candidate derived from a small molecular peptide found in scorpions. It examined the effects of both polarized and non-polarized versions of the drug on the viability of cell walls, finding that only the polarized version had a significant effect on eliminating the cell lines in all three cancers. This highlights not only the potential of Escozine® as a treatment for cancer, but the increased efficacy and bioavailability of the drug through the polarization methodology unique to Medolife Rx. Cell lines are commonly used in in vitro model systems in many drug discovery research programs. They retain most of the genetic properties of the cancer of origin and provide researchers with an indefinite source of biological material for experimental purposes (source). This study was especially significant in that Escozine® eradicated the cell lines completely, furthering the hypothesis that the drug could eliminate cancer cells in humans completely as well.
https://finance.yahoo.com/news/medolife-rx-announces-pre-clinical-130000576.html
Medolife Rx Announces Pre-Clinical Results on Drug Candidate Escozine Showing Efficacy in Eliminating Cell Lines in Ovarian and Bladder Cancer
Quanta, Inc.
Tue, March 23, 2021, 6:00 AM
BURBANK, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today clinical trial results conducted on its lead drug candidate Escozine® where the drug eradicated in vitro bladder (SCaBER) and ovarian (OVCAR-3 and IGR-OV1) cancer cell lines when administered for 24 hours.
The study was conducted at one of the most prestigious academic research facilities in the United States. The goal of the study was to assess the viability of human bladder and ovarian cancer cells treated with Escozine®, the Company’s polarized drug candidate derived from a small molecular peptide found in scorpions. It examined the effects of both polarized and non-polarized versions of the drug on the viability of cell walls, finding that only the polarized version had a significant effect on eliminating the cell lines in all three cancers. This highlights not only the potential of Escozine® as a treatment for cancer, but the increased efficacy and bioavailability of the drug through the polarization methodology unique to Medolife Rx. Cell lines are commonly used in in vitro model systems in many drug discovery research programs. They retain most of the genetic properties of the cancer of origin and provide researchers with an indefinite source of biological material for experimental purposes (source). This study was especially significant in that Escozine® eradicated the cell lines completely, furthering the hypothesis that the drug could eliminate cancer cells in humans completely as well.
https://www.nytimes.com/interactive/2021/health/bharat-biotech-covid-19-vaccine.html?searchResultPosition=1
How Bharat Biotech’s Vaccine Works
By Jonathan Corum and Carl ZimmerJan. 4, 2021
DKGR - Universal Apparel & Textile Company (OTC PINK: DKGR) Receives Three Containers Earmarked For A High-End Urban Wholesaler
January 23, 2019 / Universal Apparel & Textile Company is pleased to announce that it has produced both summer and winter clothing for a high-end, urban wholesaler.
These 3 shipments will generate well over $300,000 USD in revenue for Universal Apparel and allow it to continue with its market penetration strategy.
https://finance.yahoo.com/news/universal-apparel-textile-company-otc-130000076.html
Actually Temecula is in southwestern Riverside County, just north of San Diego. But also a great location.
My Thinkorswim platform is fine, no issues. Don't know about the TDA website
As I referenced above AZ received a slap on the wrist from the SEC ... Matt Levine in Dealbreaker magazine: "a $25,000 fine is I guess a little harsh for a scam that didn’t actually hurt anyone, but at the same time it’s a little mild for an intentionally scammy effort to steal millions of dollars, failed or not."
Interesting that Blackhawk Partners is still very much in business. AZ is still President & CEO of Blackhawk and overseeing the business of "originating, structuring & acting as equity investor in management-led buyouts, strategic equity investments, consolidations, growth capital financings, & trading key physical commodities."
It's plenty big enough a deal lol.
Tell us about the prime bank scam.
He may not be spearheading this venture - but he's part of the broader picture.
To quote from Mr. Wayne's DD:
Micheal Doherty (CEO - Woodbrook Group) and Ziad K. Abdelnour (President - Blackhawk Parnters) are both Partners at Inter-M Traders. Inter-M Traders shares the same address as Blackhawk and Woodbrook Group as well. Well also know that Felicitas Management Holdings Limited / Mutual Trust Limited / Robusto Asset Management / Hygieia Limited / CBS Global are all apart of Woodbrook Group.
Specifically, I am thinking about one of the things Janice said when asked about the potential scamy-ness of NHPI:
Ziad Abdelnour,fined $25,000 by the SEC in May 2013 and banned for 5 years from the securities industry. Matt Levine writing in Dealbreaker magazine remarked that "a $25,000 fine is I guess a little harsh for a scam that didn’t actually hurt anyone, but at the same time it’s a little mild for an intentionally scammy effort to steal millions of dollars, failed or not."
Reporting on this settlement, Dealbreaker magazine remarked that Abdelnour used to be a prominent "junk bond salesman during Michael Milken’s glory days... so he’s not bad all the time, whatever he’s up to these days." In 2016, Richtopia ranked him as one of "The 500 Most Influential CEOs".
https://wikispooks.com/wiki/Ziad_Abdelnour
It appears that ZA nowadays is something of a mover and shaker - he's President and CEO of Blackhawk Partners:
https://www.blackhawkpartners.com/
Blackhawk Partners, Inc., Investment Arm is a family office. It is a private equity firm specializing in medium sized management-led buyouts, early venture, emerging growth, mid venture, late venture, middle market, later stage, mature, buyout, strategic equity investments, equity private placements, consolidations and buildups, mezzanine and growth capital financings. It also provides advisory and trading services. The firm does not invest in ideas, startups, pre-revenue companies, private equity funds, non-profit organizations, public companies, films and motion pictures and Greenfield opportunities. It does not support diversification and bailouts. The firm primarily invests in energy, industrial, technology and security sectors. For its corporate investments, it invests in mid-size companies. The firm invests across the globe. It invests between $10 million to $100 million in companies having revenue between $10 million and $250 million and minimum EBITDA of $5 million. The firm seeks to make private or public equity investments in growth companies already cash flowing at least $2 million upon funding. It seeks to co-invest with other investors and take a board seat in its portfolio companies. The firm seeks to exit its investments after three to five years. Blackhawk Partners, Inc., Investment Arm was founded in 2008 and is based in New York, New York with additional offices in Newport Beach, California and Arlington, Virginia.
https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=39594896
Mr. Wayne has compiled some great DD here - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145180156 - part of which I have copied below but all of which should be reviewed:
Updated DD 3.0 : Woodbrook Group
Adding to Q's DD 2.0 post that's stickied: Quick summary of what we know already plus more supplemental information
Quick Recap:
Micheal Doherty (CEO - Woodbrook Group) and Ziad K. Abdelnour (President - Blackhawk Parnters) are both Partners at Inter-M Traders. Inter-M Traders shares the same address as Blackhawk and Woodbrook Group as well. Well also know that Felicitas Management Holdings Limited / Mutual Trust Limited / Robusto Asset Management / Hygieia Limited / CBS Global are all apart of Woodbrook Group.
See the sticky material at top from Q7 and Sibware for more on Inter-M and Doherty.
Lets dig into Abdelnour - This guy is no joke:
He's Founder and Chairman of Financial Policy Council - New York based Think Tank designed to formulate and promote sound & smart policies based on the principles of free enterprise and wealth creation.
http://www.financialpolicycouncil.org/
I also recently found out that he was a former President at Arab Bankers Association of North America: more on this later below
Quote:As Founder and Chairman of the Financial Policy Council, Ziad K. Abdelnour is also a Wall Street Financier, Author, Philanthropist, Activist, Lobbyist, Oil & Gas Trader & President & CEO of Blackhawk Partners, Inc., a New York based private equity “family office” that focuses on originating, structuring, advising and acting as equity investor in management-led buyouts, strategic minority equity investments, equity private placements, consolidations, buildups, and growth capital financing in companies and projects based both in the US and emerging markets and the trading of key physical commodities.
Since 1985, Mr. Abdelnour has been involved in over 125 transactions worth in aggregate over $10 billion in the investment banking, high yield bond and distressed debt markets and has been widely recognized for playing an integral role in those three key market sectors.
Mr. Abdelnour serves on the board of Elate Partners, a Chinese investment group backed by large institutional, strategic and wealthy individual investors from China.
Mr. Abdelnour also serves on the Advisory board of DPG Investments, a recognized premier multi strategy global merchant banking, alternative investment, management and advisory firm.
On a more personal level, Mr. Abdelnour, former President of the Arab Bankers Association of North America.
Mr. Abdelnour is also a regular speaker on Private Equity, Physical Commodities trading and Middle East geo-political analysis at industry conferences & TV outlets nationwide including but not limited to Fox News, Newsmax, etc… and a key “influencer” in his own right having a hard core constituency of over 2 million viewers having read his blog postings and analyses since January 2014.
Mr. Abdelnour holds an MBA in Finance from the Wharton School of Business at the University of Pennsylvania and a BS in Economics, Summa Cum Laude, from the American University of Beirut.
He was recently listed as one of the 500 Most Influential CEOs in the World.
Three things stand out here: Elate Partners / DPG Investments / Arab Bankers Association of North America
Look at the bold portion in that quote:
Elate Partners, a Chinese investment group backed by large institutional, strategic and wealthy individual investors from China.
Do you want to know who else is apart of Elate Partners? Andrew Eros - He's the CFA - Chartered Financial Analyst at Elate.
He's ALSO the Associate Real Estate Partner at guess where? Blackhawk Partners.
Then there's a company called DPG Investments: A large private investment firm led by Chairmen and CEO Daniel P. Galvanoni - WHO IS ALSO a Partner at BLACKHAWK.
To add more to this: Ziad K. Abdelnour is a Partner and INTERNATIONAL Advisor at DPG Investments.
Images below will help to tie this all together:
(.... Refer to original post by Mr. Wayne - it's well worth it I think.)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145180156
Woodbrook CEO warns against unregulated consultants in Cyprus
03 September 2018
https://www.internationalinvestment.net/internationalinvestment/news/3503608/woodbrook-ceo-warns-unregulated-consultants-cyprus#
British and Irish expatriates living in Cyprus are being targeted by several unlicensed and unregulated international financial advisory companies, the CEO of an international wealth management company has warned.
Woodbrook Group’s chief executive, Michael Doherty, spoke out today amid fears more expatriates may unwittingly be risking their savings because they are receiving advice from unregulated consultants.
Thousands of expats in Cyprus have been badly burned in the past by unregulated and unlicensed operators who sank their savings and pensions into high-risk investments without their clients’ knowledge.
Despite this, several international financial advisory firms on the island are continuing to target expatriates without having a proper license. Many of these companies are regulated by the Cyprus Insurance Company Control Service (ICCS) but are offering services that are not covered by their license, including advising on underlying investments on insurance bonds.
Doherty urged expatriates to be extra-vigilant and to ask their financial consultants some basic but extremely important questions to ensure they are dealing with a fully regulated and compliant company. These include: Do you deal with regulated providers? Where can I find your license details? Where can I find your company’s details on the regulator’s website? What are your qualifications and professional background? What are your company’s qualification requirements? Do you have a complaints policy in place? Can I access your company’s policies and procedures online?
Woodbrook Group is regulated by the Cyprus Securities and Exchange Commission (CySEC) and by the ICCS. CySEC recently approved the company’s merger with the Felicitas Management Group. The merger is a key part of the Woodbrook Group’s international expansion plan and is the harvest of months of effort to make the merged company a dynamic force in the provision of investment advice and opportunities, with a more diverse and enlarged range of services delivered through the enlarged network.
Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid GlobeNewswire•August 20, 2018
ENGLEWOOD CLIFFS, N.J., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to bertilimumab for the treatment of bullous pemphigoid (BP).
“We are incredibly gratified that bertilimumab has received Orphan Drug Designation for the treatment of bullous pemphigoid from the FDA and believe this designation, coupled with the recent positive opinion from the EMA’s Committee for Orphan Medicinal Products represent a significant regulatory milestone or bertilimumab,” commented Immune’s Chief Medical and Operating Officer, Tony Fiorino, MD, PhD. “We are focused on putting all of the manufacturing and regulatory pieces in place to launch a pivotal phase 2/3 study of bertilimumab in bullous pemphigoid next year.”
The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.
IMNP
Wow - those fire and police packages aren't cheap. Between the the demand for remote news coverage, police surveillance and military intelligence gathering, fire-fighting agencies are beginning to use drones for a variety of purposes:
https://www.firerescue1.com/emergency-response-in-the-drone-age/articles/375860018-6-takeaways-on-how-fire-departments-are-using-drones-and-the-barriers-preventing-purchase/
DRUS .... Niiiice ...
CTI BioPharma (CTIC) Stock: Falling On Clinical Update
http://cnafinance.com/cti-biopharma-ctic-stock-falling-on-clinical-update/19895
CTI Biopharma CTIC STock NewsCTI BioPharma Corp (NASDAQ: CTIC) is having a rough start to the trading session in the pre-market hours this morning after announcing the results of a Type B meeting with the FDA. While the meeting outlined a path toward approval, the stock is falling dramatically.
In a press release issued early this morning, the company announced that it recently conducted a Type B meeting with the United States Food and Drug Administration surrounding its lead product, pacritinib.
During the meeting CTIC and the FDA discussed the regulatory pathway for the treatment. In the release, the company said that based on feedback from the FDA, it plans on conducting a randomized phase 3 study of pacritinib in patients with myelofibrosis. The dosing of the study will be determined using the results of the PAC203 Phase 2 clinical study. The company expects that enrollment will be completed by 2018 with full top-line data expected in the second quarter of 2019.
In a statement, Adam R. Craig, M.D., Ph.D., President and CEO At CTIC, had the following to offer:
"We have received the clarity we requested from the FDA on a regulatory path to possible approval in the U.S., and look forward to using all available data, including pharmacokinetic analyses, to select the optimal dose for a new Phase 3 study… The new study is expected to address the unmet medical needs of patients with myelofibrosis, particularly those with severe thrombocytopenia. We plan to request an additional meeting with the FDA, after the second interim analysis, to discuss interim data from PAC203 and the design of the new Phase 3 study."
So, why is the stock falling? While the FDA did provide a path toward approval for the treatment, there are some concerns with timeline. Ultimately, investors were hoping that the current clinical study would be enough to move forward with an NDA should the study results be positive. However, with a Phase 3 trial required, investors are a little upset. Nonetheless, this may be presenting an opportunity as the IDMC did not find any drug-or-dose related safety concerns. Therefore, while a Phase 3 study will be required before the company can submit its NDA, that is the general course of action, and overall, things look positive.
ctic
Green Zebra is a leading WiFi marketing and analytics service provider for commercial real estate, cafes, bars, restaurants, hotels, and any place people socialize.
Since 2010, Green Zebra has been delivering innovative mobile marketing technologies to marketing agencies and business clients around the globe.
http://greenzebramedia.com/faq/
NNSR
Veru Inc Initiated with a Buy at Maxim Group
July 3, 2018, 7:28 AM EDT
Veru Inc (NASDAQ: VERU) received a Buy rating and a $10 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $1.95.
McCarthy wrote:
“We are initiating coverage of Veru Inc. with a $10 price target. Veru is a commercial-stage company (female/male health) with a pipeline of both 505(b)(2) and novel products that address benign prostatic hyperplasia (BPH), overactive bladder (OAB), and prostate cancer (PC).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.9% and a 39.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veru Inc with a $7.50 average price target.
https://www.smarteranalyst.com/brief/veru-inc-initiated-with-a-buy-at-maxim-group/
VERU
Veru Inc Initiated with a Buy at Maxim Group
Jason Carr-July 3, 2018, 7:28 AM EDT
Veru Inc (NASDAQ: VERU) received a Buy rating and a $10 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $1.95.
McCarthy wrote:
“We are initiating coverage of Veru Inc. with a $10 price target. Veru is a commercial-stage company (female/male health) with a pipeline of both 505(b)(2) and novel products that address benign prostatic hyperplasia (BPH), overactive bladder (OAB), and prostate cancer (PC).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.9% and a 39.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veru Inc with a $7.50 average price target.
https://www.smarteranalyst.com/brief/veru-inc-initiated-with-a-buy-at-maxim-group/
VERU
H.C. Wainwright Starts Heat Biologics (HTBX) at Buy
June 26, 2018 7:03 AM EDT
H.C. Wainwright initiates coverage on Heat Biologics (NASDAQ: HTBX) with a Buy rating and a price target of $6.00.
HTBX
H.C. Wainwright Starts Heat Biologics (HTBX) at Buy
June 26, 2018 7:03 AM EDT
H.C. Wainwright initiates coverage on Heat Biologics (NASDAQ: HTBX) with a Buy rating and a price target of $6.00.
HTBX
I think so too